Opportunistic autoimmune disorders: From immunotherapy to immune dysregulation

Annals of the New York Academy of Sciences

Volumn 1183, Issue , 2010, Pages 222-236

  Kong, Yi Chi M ^a   Wei, Wei Zen ^a   Tomer, Yaron ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; Immune dysregulation; Immunotherapeutic sequelae; Immunotherapy; Opportunistic autoimmunity

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; BETA INTERFERON; DACLIZUMAB; FLT3 LIGAND; INTERLEUKIN 2; IPILIMUMAB; JANUS KINASE; STAT PROTEIN; TICILIMUMAB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNE THYROIDITIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CARCINOID; COLON CARCINOMA; DERMATITIS; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG WITHDRAWAL; ENTEROCOLITIS; FLU LIKE SYNDROME; GRAFT VERSUS HOST REACTION; GRAVES DISEASE; HAIRY CELL LEUKEMIA; HASHIMOTO DISEASE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PERNICIOUS ANEMIA; POLYMYOSITIS; PROSTATE CANCER; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SKIN PRURITUS; SYSTEMIC LUPUS ERYTHEMATOSUS; VITILIGO;

HEPATITIS C VIRUS;

EID: 75749141271     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05138.x     Document Type: Review

References (116)

1. Pfeffer, L.M. et al. 1998. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58: 2489-2499.
2. Parmar, S. & L.C. Platanias. 2003. Interferons: mechanisms of action and clinical applications. Curr. Opin. Oncol. 15: 431-439.
3. Jonasch, E. & F.G. Haluska. 2001. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6: 34-55.
4. Baron, S. et al. 1991. The interferons. Mechanisms of action and clinical applications. JAMA 266: 1375-1383.
5. Ronnblom, L.E.,G.V.Alm&K.E.Oberg. 1991.Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 115: 178-183.
6. Burman, P., T.H. Totterman, K. Oberg & F.A. Karlsson. 1986. Thyroid autoimmunity in patients on long termtherapywith leukocyte- derived interferon. J. Clin. Endocrinol. Metab. 63: 1086-1090.
7. Manns, M.P. et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
8. Fentiman, I.S. et al. 1985. Primary hypothyroidism associatedwith interferon therapy of breast cancer. Lancet 1: 1166.
9. Russo,M.W.&M.W. Fried. 2003. Side effects of therapy for chronic hepatitis C. Gastroenterology 124: 1711-1719.
10. Okanoue, T. et al. 1996. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 25: 283-291.
11. Floreani, A. et al. 1998. Organ-specific autoimmunity and genetic predisposition in interferon-treated HCVrelated chronic hepatitis patients. Ital. J. Gastroenterol. Hepatol. 30: 71-76.
12. Ho, V., A. Mclean & S. Terry. 2008. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J. Clin. Rheumatol. 14: 166-168.
13. Mandac, J.C., S. Chaudhry, K.E. Sherman & Y. Tomer. 2006. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification. Hepatology 43: 661-672.
14. Tomer, Y., J.T. Blackard & N. Akeno. 2007. Interferon alpha treatment and thyroid dysfunction. Endocrinol. Metab Clin.North Am. 36: 1051-1066.
15. Gota, C. & L. Calabrese. 2003. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 36: 511-518.
16. Mathian, A. et al. 2005. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New ZealandWhite) F1 but not in BALB/c mice. J. Immunol. 174: 2499-2506.
17. Fattovich, G., G. Giustina, S. Favarato & A. Ruol. 1996. A survey of adverse events in 11, 241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol. 24: 38-47.
18. Kalkner, K.M. et al. 1998. Antibodies against doublestrandedDNAand development of polymyositis during treatment with interferon. QJM 91: 393-399.
19. Karlsson-Parra, A. et al. 1990. Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived interferon-alpha (IFN-alpha). Clin. Exp. Immunol. 81: 72-75.
20. Prummel, M.F. & P. Laurberg. 2003. Interferon-alpha and autoimmune thyroid disease. Thyroid 13: 547-551.
21. Koh, L.K., F.S. Greenspan & P.P. Yeo. 1997. Interferonalpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7: 891-896.
22. Roti, E. et al. 1996.Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am. J. Med. 101: 482-487.
23. Wong, V., A.X. Fu, J. George & N.W. Cheung. 2002. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin. Endocrinol. (Oxf.) 56: 793-798.
24. Watanabe, U. et al. 1994. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am. J. Gastroenterol. 89: 399-403.
25. Lisker-Melman,M. et al. 1992. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 102: 2155-2160.
26. Carella, C. et al. 2001. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J. Clin. Endocrinol. Metab. 86: 1925-1929.
27. Monzani, F., N. Caraccio, A. Dardano & E. Ferrannini. 2004. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin. Exp. Med. 3: 199-210.
28. Volpe, R. 1978. Etiology, pathogenesis, and clinical aspects of thyroiditis. Pathol. Annu. 13: 399-413.
29. Preziati,D. et al. 1995.Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur. J. Endocrinol. 132: 587-593.
30. Imagawa, A. et al. 1995. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J. Clin. Endocrinol. Metab. 80: 922-926.
31. Fentiman, I.S. et al. 1988. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur. J. Cancer Clin. Oncol. 24: 1299-1303.
32. Silvestri, F. et al. 1994. Development of autoimmune thyroid-diseases during long-term treatment of hematological malignancies with alpha-interferons. Haematologica 79: 367-370.
33. Vallisa, D. et al. 1995. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alphainterferon. Acta Haematologica 93: 31-35.
34. Satzger, I. et al. 2007. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant lowdose interferon alpha. Int. J. Cancer 121: 2562-2566.
35. Gogas, H. et al. 2006. Prognostic significance of autoimmunity during treatment ofmelanoma with interferon. N. Engl. J. Med. 354: 709-718.
36. Monzani, F. et al. 1999. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patientswithmultiple sclerosis.Eur. JEndocrinol. 141: 325-331.
37. Caraccio, N. et al. 2005. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. J. Clin. Endocrinol. Metab. 90: 4133-4137.
38. Rotondi, M. et al. 1998. Occurrence of thyroid autoimmunity and dysfunction throughout a nine- month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J Endocrinol. Invest. 21: 748-752.
39. Dalgard, O. et al. 2002. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J. Intern. Med. 251: 400-406.
40. Oppenheim, Y. et al. 2003. The effects of alpha interferon on the development of autoimmune thyroiditis in theNODH2h4 mouse. Clin. Dev. Immunol. 10: 161-165.
41. Kakizaki, S. et al. 1999. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. J. Hepatol. 30: 794-800.
42. Martocchia, A. et al. 2001. Hashimoto's disease during interferon-alpha therapy in a patient with pretreatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. Neuro. Endocrinol. Lett. 22: 49-52.
43. Nguyen, K.B. et al. 2002. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297: 2063-2066.
44. Corssmit, E.P., J. De Metz, H.P. Sauerwein & J.A. Romijn. 2000. Biologic responses to IFN-alpha administration in humans. J. Interferon Cytokine Res. 20: 1039-1047.
45. You, X.,W. Teng & Z. Shan. 1999. Expression of ICAM- 1, B7.1 and TPO on human thyrocytes induced by IFNalpha. Chin Med. J. (Engl.) 112: 61-66.
46. Arata, N., T. Ando, P. Unger & T.F. Davies. 2006. Bystander activation in autoimmune thyroiditis: studies on experimental autoimmune thyroiditis in the GFP+ fluorescent mouse. Clin. Immunol. 121: 108-117.
47. Farrar, J.D. & K.M. Murphy. 2000. Type I interferons and T helper development. Immunol. Today 21: 484-489.
48. Mazziotti, G. et al. 2005. Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: a prospective study. J. Clin. Endocrinol. Metab. 90: 4138-4144.
49. Land, K.J., J.S. Moll, M.H. Kaplan & G.S. Seetharamaiah. 2004. Signal transducer and activator of transcription (Stat)-6-dependent, but not Stat4-dependent, immunity is required for the development of autoimmunity inGraves' hyperthyroidism. Endocrinology 145: 3724-3730.
50. Mazziotti, G. et al. 2002. Is the IFN-alpha-related thyroid autoimmunity an immunologically heterogeneous disease? J. Intern. Med. 252: 377-378.
51. Nagayama, Y. et al. 2003. Prevention of autoantibodymediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J. Immunol. 170: 3522-3527.
52. Corssmit, E.P. et al. 1997. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin. Exp. Immunol. 107: 359-363.
53. Aulitzky, W.E. et al. 1991. Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2.Ann.Hematol. 62: 25-31.
54. Ajjan, R.A., P.F. Watson, R.S. Mcintosh & A.P. Weetman. 1996. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clin. Exp. Immunol. 105: 523-528.
55. Akeno, N.&Y.Tomer. 2007. Dissecting the mechanisms of interferon induced thyroiditis (IIT): Direct effects of interferon alpha on thyroid epithelial cells The 89th Meeting of the Endocrine Society,Toronto,Canda, June 2007.
56. Vial, T. & J. Descotes. 1995. Immune-mediated sideeffects of cytokines in humans. Toxicology 105: 31-57.
57. Chianese-Bullock, K.A. et al. 2005. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J. Immunother. 28: 412-419.
58. Massarotti, E.M., N.Y. Liu, J.Mier & M.B. Atkins. 1992. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am. J. Med. 92: 693-697.
59. Mcneel, D.G. et al. 2003. Pilot study on an HLA-A2 peptide vaccine using Flt3 ligand as a systemic vaccine adjuvant. J. Clin. Immunol. 23: 62-72.
60. Adams, G.P. & L.M. Weiner. 2005. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23: 1147-1157.
61. Chatenoud, L. 2006. Immune therapies of autoimmune diseases: are we approaching a real cure? Curr. Opin. Immunol. 18: 710-717.
62. Wing, K. et al. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275.
63. Waterhouse, P. et al. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.
64. Tivol, E.A. et al. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
65. Morris, G.P.,N.K.Brown&Y.M.Kong. 2009.Naturallyexisting CD4+CD25+Foxp3+ regulatory T cells are required for tolerance to experimental autoimmune thyroiditis induced by either exogenous or endogenous autoantigen. J. Autoimmun. 33: 68-76.
66. Yuan, J. et al. 2008. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. US A 105: 20410-20415.
67. Downey, S.G. et al. 2007. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13: 6681-6688.
68. Beck,K.E. et al. 2006. Enterocolitis in patientswith cancer after antibody blockade of cytotoxic T-lymphocyteassociated antigen 4. J. Clin. Oncol. 24: 2283-2289.
69. Ribas, A. et al. 2005. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J. Clin. Oncol. 23: 8968-8977.
70. Ribas, A. et al. 2007. Tremelimumab (CP-675, 206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12: 873-883.
71. Ribas, A. et al. 2008. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675, 206) and chemotherapy)temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol. 26: 485s (May 20, suppl: abstract).
72. Weber, J. 2008. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX- 010). Oncologist 13(Suppl 4): 16-25.
73. Jacobson, D.L. et al. 1997. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84: 223-243.
74. Blansfield, J.A. et al. 2005. Cytotoxic T-lymphocyteassociated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. 28: 593-598.
75. Ridruejo, E., A.F. Christensen & O.G. Mando. 2006. Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. Eur. J. Gastroenterol. Hepatol. 18: 693-694.
76. Caturegli, P. et al. 2008. Pituitary autoimmunity: 30 years later. Autoimmun. Rev. 7: 631-637.
77. Ueda,H. et al. 2003.Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511.
78. Maker, A.V., P.Attia&S.A.Rosenberg. 2005.Analysis of the cellularmechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175: 7746-7754.
79. Kong, Y.M. et al. 2009. Autoimmune thyroiditis as an indicator of autoimmune sequelae during cancer immunotherapy. Autoimmun. Rev. 9: 28-33.
80. Wei, W.-Z. et al. 2005. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+CD25+ regulatory T cell-depleted mice. Cancer Res. 65: 8471-8478.
81. Kong, Y.M. et al. 1996. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLADRB1 ?0301 (DR3) gene. J. Exp. Med. 184: 1167-1172.
82. Jacob, J.B. et al. 2007.Control ofHer-2 tumorimmunity and thyroid autoimmunity by MHC and regulatory T cells. Cancer Res. 67: 7020-7027.
83. Jacob, J.B. et al. 2009. Tumor regression followingDNA vaccination andregulatoryTcell depletion in neutransgenic mice leads to an increased risk for autoimmunity. J. Immunol. 182: 5873-5881.
84. Morris, G.P., L. Chen & Y.M. Kong. 2003. CD137 signaling interferes with activation and function of CD4+CD25+ regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell. Immunol. 226: 20-29.
85. Morris, G.P. & Y.M. Kong. 2006. Tolerance to autoimmune thyroiditis: CD4+CD25+ regulatory T cells influence susceptibility but do not supersede MHC class II restriction. Front. Biosci. 11: 1234-1243.
86. Alinari, L. et al. 2007. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 26: 3644-3653.
87. Shapiro, R. et al. 2005. Immunosuppression: evolution in practice and trends, 1993-2003. Am. J. Transplant. 5: 874-886.
88. Lisak, R.P. & J-I. Kira. 2009. Multiple sclerosis. In Inter. Neurology: A clinical Approach. Lisak, R.P., D.D. Truong, W. Carroll & R. Bhidayasiri, Eds.: 366-374. Wiley-Blackwell Publishing, Hoboken, NJ.
89. Durelli, L. et al. 2001. Thyroid function and autoimmunity during interferon beta-1b treatment: amulticenter prospective study. J. Clin. Endocrinol.Metab. 86: 3525-3532. (Pubitemid 32755939)
90. Clerico, M. et al. 2008. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clin. Neurol. Neurosurg. 110: 878-885.
91. Hauser, S.L. 2008.Multiple lessons for multiple sclerosis. N. Engl. J. Med. 359: 1838-1841.
92. Coles, A.J. et al. 2006. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 253: 98-108.
93. Coles, A.J. et al. 1999. Pulsed monoclonal antibody treatment and autoimmune thyroid disease inmultiple sclerosis. Lancet 354: 1691-1695.
94. Coles, A.J. et al. 2008. Alemtuzumab vs. interferon beta- 1a in earlymultiple sclerosis.N.Engl. J.Med. 359: 1786-1801.
95. Loh, Y. et al. 2007. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 109: 2643-3548
96. Burt, R.K. et al. 2008. Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned? J. Autoimmun. 30: 116-120.
97. Waldmann, T.A. 2007.Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol. 27: 1-18.
98. Pearl, J.P. et al. 2005. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am. J. Transplant. 5: 465-474.
99. Kirk,A.D. et al. 2006.Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am. J. Transplant. 6: 1084-1085.
100. Walsh, M., A. Chaudhry & D. Jayne. 2008. Longterm follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis. 67: 1322-1327.
101. Lorenzi, A.R. et al. 2008. Morbidity and mortality in rheumatoid arthritis patients with prolonged therapyinduced lymphopenia: twelve-year outcomes. Arthritis Rheum. 58: 370-375.
102. Vital, E.M. & P. Emery. 2008. The development of targeted therapies in rheumatoid arthritis. J. Autoimmun. 31: 219-227.
103. Lundin, J. et al. 2004. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as firstline therapy for B-cell chronic lymphocytic leukaemia. Leukemia 18: 484-490.
104. Wing, M.G. et al. 1996. Mechanism of first-dose cytokine-release syndromebyCAMPATH1-H: involvement of CD16 (FcgammaRIII) andCD11a/CD18 (LFA- 1) on NK cells. J. Clin. Invest 98: 2819-2826.
105. Nabozny, G.H. & Y.M. Kong. 1992. Circumvention of the induction of resistance in murine experimental autoimmune thyroiditis by recombinant IL-1. J. Immunol. 149: 1086-1092.
106. Verginis, P., H.S. Li & G. Carayanniotis. 2005. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulinspecific CD4+CD25+ T cells. J. Immunol. 174: 7433-7439.
107. Watanabe, T. et al. 2006. CD52 is a novel costimulatory molecule for induction of CD4 +regulatory T cells. Clin. Immunol. 120: 247-259.
108. Hequet,O. et al. 2003.Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. Bone Marrow Transplant. 32: 89-95.
109. Bohgaki, T., T. Atsumi & T. Koike. 2008. Autoimmune disease after autologous hematopoietic stem cell transplantation. Autoimmun. Rev. 7: 198-203.
110. Blaise, D. et al. 2007. Current status of reducedintensity- conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 92: 533-541.
111. Hsiao, L.T., J.H. Liu, C.C. Yen, et al. 2001. Relapse of Graves' disease after successful allogeneic bone marrow transplantation. Bone Marrow Transplant. 28: 1151-1153.
112. Muraro, P.A. et al. 2005. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation inmultiple sclerosis patients. J. Exp. Med. 201: 805-816.
113. Dudley, M.E. et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
114. Pfohler, C. et al. 2008. 'Autoimmunity' is not always associatedwith prolonged survival inmelanoma patients. Br. J. Dermatol. 159: 735-736.
115. Sondak,V.K.&L.E. Flaherty. 2008. Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for? Lancet 372: 89-90.
116. Maker, A.V. et al. 2005. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 12: 1005-1016.